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Abstract (213 words) 
Background: Diabetes is a complex progressive disease characterised by chronic 
hyperglycaemia and dyslipidaemia associated with endothelial dysfunction. Oxidised LDL 
(Ox-LDL) is elevated in diabetes and may contribute to endothelial dysfunction. The aim of 
this study was to relate the serum levels of Ox-LDL with endothelial dysfunction in 
streptozotocin (STZ)-diabetic rats and to further explore the changes in endothelial nitric oxide 
synthase (eNOS) and caveolin-1 (CAV-1) expression in primary aortic endothelial cells (ECs).  
Methods: Diabetes was induced with a single intraperitoneal injection of STZ in male Wistar 
rats. During the hyperglycaemic diabetes state serum lipid markers, aortic relaxation and aortic 
ECs eNOS and CAV-1 protein expression was measured.  
Results: Elevated serum Ox-LDL (STZ 1486  78.1 pg/ml vs control 732.6  160.6pg/ml, 
p<0.05) was associated with hyperglycaemia (STZ 29  0.9 mmol/L vs control: 7.2  0.2 
mmol/L, p<0.001) and hypertriglyceridemia (STZ 9.0  1.5 mmol/L vs control: 3.0  0.3 
mmol/L, p<0.01) in diabetic rats. A significant reduction was observed in STZ-diabetic aortic 
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endothelial cell eNOS and CAV-1 of 40% and 30% respectively, accompanied by a 
compromised STZ-diabetic carbachol-induced vasodilation (STZ 29.6  9.3% vs control 77.2 
 2.5%, p<0.001).  
Conclusions: The elevated serum Ox-LDL in hyperglycaemic STZ-diabetic rats may 
contribute to diabetic endothelial dysfunction, possibly through downregulation of endothelial 
CAV-1 and eNOS. 
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1. Introduction (410 words) 
The incidence of diabetes mellitus is increasing throughout the world and numbers are 
expected to reach 592 million by the year 2035, mainly because of the increase in obesity [1]. 
Despite the differences in aetiology, clinical presentation and disease prevalence, secondary 
complications, such as endothelial dysfunction, occur in both type 1 and 2 diabetes. Diabetes 
complications are largely resistant to treatments posing a huge economic burden to the health 
system and society. Endothelial dysfunction renders diabetics vulnerable to limb infections and 
end-organ damage such as nephropathy, neuropathy as well as retinopathy [2]. As yet, there 
are no biomarker predictors to indicate endothelial dysfunction in diabetes.  
In recent decades, strategies for managing vascular complications associated with 
diabetes have moved away from a “glucocentric” approach to address additional risk factors 
that contribute to the development and progression of atherosclerosis. The presence of an 
atherogenic lipid profile is common in diabetic patients and is characterised by elevated plasma 
triglyceride (TGs) levels, low levels of high-density lipoprotein (HDL)-cholesterol and a 
preponderance of small dense LDL particles. Oxidised LDL (Ox-LDL) is a key component in 
the genesis of the atherosclerotic lesion and is cytotoxic to various cell types including 
endothelial cells (ECs) and therefore is suggested to contribute to endothelial dysfunction [3]  
Caveolae form highly organised microdomains in the ECs plasma membrane through 
providing docking sites for numerous signalling molecules, such as endothelial nitric oxide 
synthase (eNOS) [4]. Caveolin-1 (CAV-1) is a principal protein and marker found in the 
endothelial caveolae [5] and is co-localised with eNOS in cultured bovine aortic ECs [6]. 
Furthermore, both CAV-1 and eNOS are significantly downregulated in diabetic kidneys [7] 
linked to decreased renal eNOS-derived nitric oxide and diabetic cavernosal tissues decreased 
NO mediated relaxation leading to erectile dysfunction [8]. Disruption of endothelial caveolae 
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leading to eNOS uncoupling and diminished flow-mediated dilation in coronary arterioles of 
diabetic patients has also been observed [9].  
 
We have previously shown that abnormal vascular responsiveness in STZ-diabetic 
rats are attributed in part to the overproduction of reactive oxygen species [10]. Here we aim 
to investigate the alteration in non-HDL, HDL, Ox-LDL, cholesterol and TGs serum 
concentrations, and whether it is associated with changes in the expression of eNOS and 
CAV-1 proteins in endothelial cell together with aortic vascular dysfunction using the STZ-
diabetic rat model. 
 
2. Materials and Methods (1552 words) 
2.1 Materials and Reagents 
Streptozotocin (STZ, S-0130) was purchased from Sigma-Aldrich (UK). Ox-LDL sandwich 
ELISA (SEA527Ra) were from Cloud clone corp. LDL, HDL, cholesterol and TGs Randox 
(Rx) Monza kits (CH 202, CH 203) were from Randox (www.randox.com). All culture 
reagents were from Fischer Scientific. The rabbit primary antibody for eNOS (PA3-031A) 
and CAV-1 (PA5-17447) were obtained from Thermo Fisher Scientific. The fluorescence 
goat secondary anti rabbit antibody (FI-1000) was obtained from Vector laboratories. All 
other chemicals were of analytical grade and were obtained from local companies. 
 
2.2 Induction of diabetes 
This study was approved by the Institutional Animal Welfare and Ethics review 
committee and conducted in accordance with guidelines established by the Animals Scientific 
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Procedures Act, 1986 and European directive 2010/63/EU carried out under project licence 
PPL70/7732.  Male Wistar rats (325-425g, Charles River, UK) were given a single injection of 
65mg/kg Streptozotocin (STZ, Dose volume 10ml/kg); dissolved in 20 mM citrate buffer (pH 
4.5) intraperitoneally. Control rats received injections of citrate buffer alone. Animals were 
housed in pairs with water and food (5LF2 10% protein LabDiet, switched to 5LF5 22% protein 
Labdiet on day of STZ injection) freely available throughout the study. For 48 hours following 
STZ or control injection, 2% sucrose solution was also provided to avoid the initial 
hypoglycaemia that is seen following STZ. Diabetes was confirmed on day 7 and terminal day 
(in the 2nd week post-injection) by testing a drop of tail vein blood, obtained by a needle prick 
of conscious rats, measured using an Accu-check blood glucose monitor. Rats showing an 
elevated blood glucose of >16mmol/L on day 7 were considered diabetic. Rats were euthanized 
by schedule 1 procedure (CO2 asphyxiation) and thoracic aorta blood was sampled and left to 
coagulate in Eppendorf tubes before being centrifuged at 13000rpm for 5 minutes. The 
supernatant (the serum) was then transferred to another Eppendorf tube and stored at -80oC for 
up to 12 months. Aortas were freshly isolated for vasoactive responses or endothelial cell 
isolation and primary culture.  
  
2.3 Oxidative LDL (Ox-LDL) determination in serum 
All samples were analysed through sandwich ELISA according to the manufacturer’s 
instructions (Cloud clone corp, SEA527Ra). The OxLDL ELISA assay has high sensitivity and 
specificity for detection of Oxidized Low-Density Lipoprotein (OxLDL) with a detection range 
of 31.25-2000pg/mL. The immunogen used in the ELISA is native protein of Cu2+ oxidized 
LDL.  
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2.4 Non HDL, HDL, TGs, cholesterol determination in serum  
Serum samples were analysed for HDL, cholesterol and TGs using Randox (Rx) Monza 
kits according to the manufacturer’s instructions (www.randox.com, CH 202, CH 203). Prior 
to assaying each marker, calibrations were carried out and all samples were allowed to thaw on 
ice, centrifuged at 4000 rpm for 5 min and kept on ice until assay. Briefly, for total serum 
cholesterol, 500ul of Chol R1 reagent was mixed with 50ul of serum sample, left at 37oC for 
10 min. For serum HDL, 500ul of HDL R1a precipitant reagent was inverted with 200ul serum 
sample and left to stand at room temp for 10min. The sample was then centrifuged at 4000rpm 
for 10min and 50ul supernatant added to 500ul of Chol R1 reagent, left at 37oC for 10min. For 
serum TGs, 500ul of R1b reagent was mixed with 5ul serum sample, left at 37oC for 10 min. 
All prepared samples were then transferred into semi micro-cuvettes and absorbance levels 
read at 510nm (HDL, Chol) and 546nm (TGs). The Friedewald equation cannot be used when 
TGs values are ≥400 mg/dl because it tends to underestimate absolute LDL concentrations 
[11]. Given the elevated TGs (approximately 9 mmol/ 797 mg/dl) in our STZ rats non high-
density lipoprotein (non-HDL) cholesterol concentrations (which includes very-low-density 
lipoprotein VLDL, intermediate-density lipoprotein IDL and low-density lipoprotein LDL), 
were calculated by subtracting the HDL cholesterol from total cholesterol values.   
2.5 Aortic vascular function  
Aortic endothelial function was evaluated in STZ-diabetic rats and control rats (in the 
2nd week post-injection). Briefly, freshly isolated aorta was cut into approximately 2-3mm 
wide rings which were threaded by superior and inferior loops where the inferior thread loop 
was attached to a fixed hook and kept suspended in a Bennett isolated tissue organ bath filled 
with Krebs solution pH 7.4 at 37°C±1°C and gassed with 95% O2/ 5% CO2. The superior 
loop was attached through long terminal thread to FT-100 force transducer under 1g tension 
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force. FT-100 force transducer transmitted tissue response to iWORKS amplifier that 
generated electrical signals to be recorded through Labscribe software from iWORKS 
(version 1.817). Thereafter, aortic rings were left to equilibrate for 60-90 minutes with 
approximately 15 minutes washing intervals. Aortic rings were then pre-contracted with 
noradrenaline (Sigma Aldrich, A7257) (NA; 300nM) before being treated with carbachol 
(CC) (Sigma Aldrich, C4328) to generate a cumulative concentration response curve (30nM- 
300µM). 
 
2.6 Expression of eNOS and CAV-1 in Primary endothelial cells  
Cell studies were conducted to determine the expression level of eNOS and CAV-1 in 
primary rat aortic ECs (in the 2nd week post-injection) through laser scanning confocal 
microscopy (LSCM) based immunocytochemistry. Primary aortic ECs were isolated 
aseptically. Briefly, rat aorta was freshly isolated and plunged into sterile Hank’s balanced 
salt solution (HBSS) (Fisher-Scientific, 10227632). The aorta was cleaned from the 
connective tissue (de-adventitia) using autoclaved forceps and scissors and cut into small 
rings (2-3mm long). Afterward, the aortic rings were transferred into a sterile tube containing 
warm serum free medium 199 (Fisher-Scientific, 10696733) (10ml) containing collagenase (1 
mg/ml) (Sigma Aldrich, C1639) and agitated for 90 minutes at 37°C. Afterward, 1 ml of new 
born calf serum (Fisher-Scientific, 10014173) was added to the collagenase activity. A wide 
mouth pipette was used to forcibly flush the aortic rings to dislodge any possible loosely 
hanging ECs. The aortic rings were then discarded and the media 199 that contains new born 
calf serum, collagenase and ECs was then centrifuged for 5-minutes at 10000rpm at 25°C. 
The supernatant was discarded and the small pellet containing ECs was then re-suspended in 
collagenase free media 199 (3ml). The re-suspended pellet was then plated on rat tail 
collagen (Type I) (Fisher-Scientific, C7661) coated t-25 flask and the flask was left in the 
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incubator (5% CO2, 37°C) for 25-30 minutes. The media was then aspirated, and the recently 
adhered cells were washed twice with HBSS to remove any possible impurities, debris or 
aortic smooth muscle cells (ASMCs). The flask was then added with complete DMEM (low 
glucose 1 g/L) (3ml) (Fisher-Scientific, 10135082) containing horse serum (15%) and 
newborn calf serum (4%), endothelial cell growth factor 75micg/ml (Fisher-Scientific, 
E0760), and heparin powder (0.005% w/v) (Fisher-Scientific, H3149) in addition to 
streptomycin-penicillin 1x (Fisher-Scientific, 10101043). The ECs were grown to 
approximately 80% confluence within 7 days. Afterward, the confluent primary ECs were 
trypsinised (Fisher-Scientific, 10217723) and seeded on autoclaved poly-L-lysine (Sigma 
Aldrich, P4932) coated glass coverslips (0.16-0.19mm thick). ECs were grown on the 
coverslips for two days till reaching approximately 70% confluency. The ECs were labelled 
with acetylated low-density lipoprotein (dil-Ac-LDL) as recommended by the manufacturer 
(Alfa Aesar, BT-902). The acetylated-LDL is taken-up selectively by the ECs that hydrolyse 
the acetyl bond to release the fluorescence LDL which is trapped intracellularly, endowing 
red fluorescence to the ECs.  
The coverslips were then incubated with paraformaldehyde (4% in HBSS pH 7.4) in 
the dark at room temperature for 1 hour to fix the ECs. Afterward, the ECs were permealised 
through Triton-X100 (0.5% in HBSS) incubation for 10 minutes in the dark at room 
temperature. The coverslips were washed 3 times with HBSS. The ECs were incubated with 
rabbit primary antibody (1:100) for eNOS (Thermo Fisher Scientific, PA3-031A) or CAV-1 
(Thermo Fisher Scientific, PA5-17447) in blocking solution composed of phosphate buffer 
saline pH 7.4, bovine serum albumin (BSA) (Sigma Aldrich, A9418) (1%) and foetal calf 
serum (FCS) (Thermo Fisher Scientific, 10500-064) (2%) for overnight in 4°C. Thereafter, 
the ECs were washed with HBSS before being incubated with the fluorescence goat 
secondary anti rabbit antibody (Vector laboratories, FI-1000) (1:1000) for 2 hours at room 
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temperature. The coverslips were then washed with HBSS and mounted on microscope glass 
slides with a drop of mounting media containing DAPI (Vector laboratories, H-1500) which 
stains the nucleus in blue. The ECs were visualised with Nikon C1 CLSM and EZ-C1 silver 
version 3.9 software. The images are then uploaded to ImageJ 1.46r software for quantitative 
analysis. The expression of eNOS and CAV-1 was quantified through measuring the 
fluorescence intensity per cell (n= 3-4 cells/coverslip), and then normalised to the intensity of 
the control cells for each antibody. 
2.7 Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM). ‘n’ refers to 
independent values, not replicates. Data subjected to statistical analysis have n of at least 
4/group. Data was analysed by either an unpaired t test or repeated measures or two-way 
ANOVA followed by Bonferroni’s post-hoc test, using GraphPad prism version 5.00. 
Differences were considered to be statistically significant when p=<0.05. p values lower than 
0.05 are expressed as P<0.01 or 0.001. Carbachol (CC, 30nM- 300µM) induced relaxation of 
aortic rings is normalized to % relaxation of noradrenaline EC80 (300nM) contraction in STZ-
diabetic rats’ aortic rings and control rats’ aortic rings. Primary aortic ECs were plated onto 
poly-l-lysine coated glass coverslips and visualised under LSCM. The confocal microscopy 
representative images were quantitatively analysed through ImageJ software (version 1.46r) 
and statistically analysed through Graph Pad prism (version 5.00). 
3. Results (524 words) 
3.1 Effect of STZ on serum glucose, non-HDL, Ox-LDL, TGs, HDL and cholesterol  
Administration of STZ resulted in hyperglycaemia in all rats by day 7 and was sustained 
throughout the study. Blood glucose was significantly elevated in STZ-diabetic rats (> four-
fold) as early as day 7 compared with age-matched control rats (STZ-diabetic: 29  0.9 
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mmol/L; control: 7.2  0.2 mmol/L p<0.001, Figure 1). Animal health was closely monitored 
daily, and it was noted that although the STZ- diabetic animals failed to increase body weight 
they did manage to maintain their starting weights (data not shown). All STZ diabetic animals 
showed typical symptoms of the disease such as polydipsia, polyuria, glycosuria as well as 
hyperglycaemia (data not shown). 
Compared with the control group, the levels of Ox-LDL and TGs were significantly 
increased in serum from STZ-diabetic rats (Figures 2b, c). Serum non-HDL cholesterol in STZ-
diabetic rats just failed to reach significance compared with control rats (p=0.1, Figure 2a) 
whilst TGs increased three-fold (Figure 2c). A small but significant increase in total serum 
cholesterol was noted (Figure 2e), although serum HDL cholesterol remained unchanged in 
STZ-diabetic rats compared with controls (Figure 2d). 
3.2 Effect of STZ on carbachol induced aortic vascular relaxation  
The increase in Ox-LDL and TGs was accompanied by a significant STZ-diabetic aortic 
dysfunction as shown in Figure 3. Aortic rings pre-contracted with 300nM noradrenaline from 
STZ-diabetic rats showed a significant increase in vasoconstriction (0.37 ± 0.02g, *P<0.05) 
compared with control rat aorta (0.30 ± 0.02g,) and a significant decrease in vascular relaxant 
response to carbachol (EC50= 0.8 ± 0.4µM & Emax= 29.6 ± 9.3%, *** P˂0.001) compared with 
control rat aorta (EC50= 0.6µM ± 0.2µM & Emax = 77.2 ± 2.5%). In separate experiments control 
rat aortic rings pre-incubated with L-NAME (100µM) for 30 minutes (Emax = 11.3 ± 1.6%), 
and when endothelium was denuded (Emax = 12.5 ± 4.7%), both showed a significant decrease 
(*** P˂0.001) in vascular relaxation in response to carbachol when compared with control rat 
aorta (Emax = 77.2 ± 2.5%, data not shown). These data provide a causal link between altered 
nitric oxide synthase and altered aortic vasorelaxation. 
3.3 Effect of STZ on aortic endothelial cell eNOS staining 
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To investigate whether the reduced aortic vasorelaxation response in STZ-diabetic 
rats might be due to dysfunction in nitric oxide (NO) generation by endothelial cells (ECs) 
we investigated primary cultures of ECs from control and STZ-diabetic rat aorta. The LSCM 
images of EC cells stained with eNOS antibody showed distinct distribution of eNOS around 
the nucleus and at the edges of the plasma membrane (indicated by yellow arrows in Figure 
4a). Control ECs showed significantly higher eNOS expression compared to STZ-diabetic 
ECs (control N=5 average expression 100.0 ± 4.3% vs STZ-diabetic N=6, 62.1 ± 5.8%) 
(Figure 4c). 
3.4 Effect of STZ on aortic endothelial cell CAV-1 staining 
Caveolae are 50- to 100-nm diameter lipid raft invaginations in the endothelial cells 
membrane. Caveolae form approximately 95% of the ECs surface invaginations and function 
as a signalling platform that facilitates interactions of signalling molecules [12]. Among the 
signalling molecules docked in the caveolae is eNOS [6]. CAV-1 is a major protein component 
of the endothelial caveolae. Previous studies have shown that eNOS and CAV-1 are co-
localised in rat kidneys and cultured bovine aortic endothelial cells [6, 7]. Accordingly, we 
hypothesised that the levels of eNOS and CAV-1 proteins are altered in STZ-diabetic rat aortic 
ECs. Immunocytochemistry studies were conducted which showed significant CAV-1 
downregulation and disruption in STZ-diabetic aortic ECs (Figure 5a, b). Total CAV-1 
expression showed a significant reduction in STZ-diabetic rat aortic ECs compared with 
control rat aortic ECs (Control, N=5 average expression 100.0 ± 3.0% vs STZ N=4, 73.8 ± 
4.3%) (Figure 5c). 
 Discussion (1132 words) 
In this study, STZ-diabetic rats developed symptoms of diabetes such as 
hyperglycaemia by day 7 which was sustained over 24 days (Figure 1), consistent with others 
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[13]. Furthermore, we have previously shown endothelial dysfunction is evident as early as 8 
days following STZ injection  and hence lipid markers and endothelial dysfunction were 
measured during the 2nd week post STZ injection in this study [14].  
Herein, we demonstrated a state of hyperlipidaemia (elevation of serum TGs, 
cholesterol, Ox-LDL) in this type 1 model of diabetes. Compared with the control group, the 
levels of Ox-LDL and TGs were significantly increased in serum from STZ-diabetic rats 
(Figure 2). However, serum non-HDL cholesterol (which include LDL, VLDL, ILDL) levels 
in STZ rats, although elevated, did not show a significant difference when compared with 
control levels (p=1.0). TGs increased three-fold in serum in line with the four-fold increase in 
blood glucose (Figure 2). A small but significant increase in total cholesterol was noted, 
although HDL levels remained unchanged, in STZ-diabetic rats compared with controls 
(Figure 2). This hyperlipidaemia is consistent with previous findings in non-insulin treated type 
1 diabetic patients [15] and type 1 diabetes models (with no insulin replacement therapy) [16, 
17]. The elevated serum TGs and Ox-LDL in STZ-diabetic rats may be attributed to increased 
production and decreased clearance of triglyceride-rich lipoproteins. In adipose tissues, insulin 
suppresses lipolysis by inhibiting the activity of hormone sensitive lipase, which catalyses the 
mobilisation of free fatty acids from stored TGs [18]. The STZ-mediated destruction of the 
pancreatic β-cells results in an insulinopaenic state in STZ-diabetic rats and hence the lack of 
insulin will result in an increased lipolysis of triglyceride-rich lipoproteins (LDL, TGs) and 
furthermore given carbohydrates can no longer be utilised efficiently as an energy source this 
leads to a greater reliance on energy from fat and protein to meet the energy demands of the 
animal [19].  
Similar to previous findings in type 2 diabetic patients, we observed a relationship 
between serum Ox-LDL concentrations and serum TGs concentrations in our STZ-diabetic rats 
[18]. In patients with type-2 diabetes, hyperglycaemia enhances the oxidative stress, further 
# DMRR-17-RES-322 
13 
 
modifying LDL into Ox-LDL, which is likely occurring in our type 1 hyperglycaemic STZ 
diabetic rats. This association is seen even in healthy volunteers where transiently increased 
plasma glucose levels correlates with higher oxidation of LDL [20]. Moreover, an inverse 
relationship has been observed between LDL sizes and circulating Ox-LDL in type 2 diabetic 
patients [21]. In fact, the formation of small, dense LDL particles is mostly observed in 
hypertriglyceridaemic states [22]. Therefore, both the increase in triglycerides and oxidation 
of LDL in our STZ type 1 diabetic rats indicates that there may be a predominance of small 
dense LDL (increased number of LDL particles). Small dense LDL particles are likely to be 
taken up more easily across the endothelium into the arterial wall, compared to larger LDL 
particles. Studies often express levels of Ox-LDL in different formats and units of measurement 
(e.g. in mg/dl) [23] as in our study, or Ox-LDL to total LDL [18]. Further different assays use 
antibodies detecting different epitopes on Ox-LDL, so caution needs to be applied when 
interpreting results and comparing across studies [24].  
Our dyslipidaemic STZ-diabetic rats showed endothelial dysfunction through impaired 
cholinergic-induced endothelium-dependent aortic vasodilation (Figure 3) consistent with [25]. 
Increased circulating Ox-LDL in our STZ-diabetic rats may directly damage arteries, possibly 
via the Ox LDL receptor, LOX-1, which is up-regulated in the vascular endothelium of diabetic 
animals, leading to foam cell formation and plaque development, as a causal relationship 
between Ox-LDL and atherosclerosis is well established [26]. Moreover, an increased Ox-
LDL/apoB ratio has been associated with macrovascular disease and peripheral neuropathy in 
Japanese patients with type 2 diabetes [18]. Ox-LDL molecules are recognised by the CD36 
endothelial scavenger receptor that facilitates the uptake and the endocytosis of Ox-LDL [27]. 
Ox-LDL molecules are cholesterol acceptors that compete with caveolae to deplete the 
caveolae from cholesterol and hence causes caveolae disruption displacing eNOS [28]. Such 
caveolae disruption would inhibit eNOS attachment to CAV-1 and subsequent eNOS activation 
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[28] therefore yielding endothelial dysfunction, as observed seen in our STZ diabetic rats 
(Figure 3) and depicted in Figure 6. Furthermore, the elevated serum Ox-LDL in our STZ-
diabetic rats may directly inhibit eNOS attachment to CAV-1 and hence reduce the eNOS 
coupling with CAV-1 that culminates in compromised eNOS activity and subsequent NO 
release and vasodilation [29]. 
In support of this hypothesis, our immunocytochemistry studies showed significant 
downregulation of eNOS and CAV-1 in cultured primary STZ-diabetic aortic ECs (Figures 4 
& 5). Additionally, eNOS showed corresponding distribution to CAV-1 in control aortic ECs, 
perinuclear and at the edges of the plasma membrane (Figures 4 & 5) revealing the overlapping 
distribution of these two essential elements, consistent with Wang et al. [6] findings of eNOS 
and CAV-1 co-localisation in bovine aortic ECs. Interestingly this downregulation is not 
consistent with Elçioğlu et al., [30] who report an increased expression of CAV-1 in STZ-
diabetic aorta, although their Western blots of whole aorta is likely to indicate accumulation of 
CAV-1 protein in the predominant vascular smooth muscle cells rather than endothelial cell 
caveolae. These authors note STZ impairs aortic vascular relaxation, but they do not investigate 
CAV-1 expression in aortic ECs.  This is the first report of STZ-diabetes induced eNOS and 
CAV-1 downregulation in primary rat aortic ECs. 
Disruption of endothelial caveolae and reduced CAV-1 has been found in coronary 
arteries of diabetic patients, and in human coronary endothelial cells under high glucose, linked 
to ONOO (-) formation and eNOS uncoupling and diminished flow-mediated dilation [9]. 
There is limited information on functional interactions of CAV-1 and eNOS in the 
microdomain. The decrease in CAV-1 and eNOS aortic EC expression in diabetes may lead to 
a decrease in eNOS activity and NO release, resulting in impaired endothelium dependent 
aortic vasodilation. This finding might be attributed to inhibited phosphatidylinositol 3-
kinase/Akt (PI3K-Akt) pathway since PI3K inhibitor, wortmannin was shown to inhibit the 
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eNOS and CAV-1 translocation to the plasma membrane in bovine aortic ECs [6] (Figure 6). 
Interestingly, the 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors, simvastatin and 
lovastatin protect eNOS activity from Ox-LDL-induced downregulation [31]. HDL binds 
mainly on scavenger receptor class B isoform I (SR-BI) where it delivers the circulating 
cholesterol to the caveolae maintaining the caveolae integrity and enhancing eNOS activity 
which may support a benefit for increasing the HDL/Cholesterol ratio [32]. The mechanism of 
CAV-1 and eNOS downregulation and reduced eNOS activity in diabetic aortic ECs needs 
further investigation.   
Conclusion  
In summary, STZ-diabetic rats showed significant endothelial dysfunction 
demonstrated by impaired carbachol-induced vasodilation. Such endothelial dysfunction was 
accompanied by eNOS and CAV-1 downregulation in STZ-diabetic aortic primary ECs. STZ-
diabetic rats showed a significant increase in serum Ox-LDL level which may contribute to the 
oxidative and carbonyl stress associated with diabetic eNOS and CAV-1 endothelial 
dysfunction.   
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Figure 1. Effect of STZ diabetes on blood glucose (mmol/L) at day 0, day 7 and day of death 
(2nd week post injection). Significantly different from control group is denoted by ***= 
p<0.001, $$$=p<0.001 versus day 0 using unpaired Student t-test. Data are presented as mean 
± S.E.M (control n=16, STZ n=24). 
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Figure 2. Effect of STZ diabetes on: a) serum non-HDL (mmol/L) b) serum Ox-LDL (pg/ml) 
c) serum TGs (mmol/L) d) serum HDL (mmol/L) and e) serum total cholesterol (mmol/L) at 
2nd week post injection. Data are presented as mean ± S.E.M (n=4 for Ox-LDL; n=24 for all 
other serum markers). Significance is denoted by *= p<0.05, **=p<0.01 different from control 
group, using unpaired 2-tailed t test. Serum non-HDL (panel a) STZ versus control was close 
to significance at p=0.1. 
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Figure 3. Concentration response curves to carbachol mediated relaxation, normalized (%) to 
Noradrenaline (NA) EC80 (300nM) contraction in aorta rings from STZ-diabetic rats vs control 
rats at 2nd week post injection. Data were analysed through Bonferroni’s two-way repeated 
measures ANOVA. Data presented as mean ± SEM (N=5-6). Significance is represented as 
*** P˂0.001 versus control. FBC: final bath concentration. 
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Figure 4. eNOS expression in primary endothelial cells from control and diabetic rat aorta 
under laser scanning confocal microscope. Panels a and b are control and STZ diabetic aortic 
endothelial cells respectively. Endothelial cells were probed with DAPI to label the nucleus 
in blue and marked with acetylate oxidised LDL (Ac-Ox-LDL) giving the cells the red colour 
(a1 & b1). Anti eNOS primary antibody probed with secondary fluorescence antibody 
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showed distinct distribution around the nucleus and at the edge of plasma membrane in 
control naïve aortic endothelial cells as pointed by the arrows (a2). STZ-diabetic endothelial 
cells showed disrupted eNOS distribution with less fluorescence light emission (b2). Images 
were combined to merge endothelial marker (red), nucleus marker (blue) and eNOS 
fluorescence antibody (green) (a3 & b3). c) Quantitative analysis of eNOS immunoreactivity. 
Data is mean +/- SEM (N= 5-6) of total eNOS expression (% of control) in rat aortic 
endothelial cells. STZ diabetic ECs showed a significant reduction in eNOS expression 
compared with control aortic ECs. Significance is represented as *** P˂0.001 versus control 
when analysed through two tailed unpaired student t-test. 
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Figure 5. Caveolin-1 (CAV-1) expression in primary endothelial cells under laser scanning 
confocal microscope. Panels a and b are control and STZ diabetic aortic endothelial cells 
respectively. Endothelial cells were probed with DAPI to label the nucleus in blue and marked 
with acetylate oxidised LDL (Ac-Ox-LDL) giving the cells the red colour (a1 & b1). Anti 
caveolin-1 primary antibody probed with secondary fluorescence antibody showed distinct 
CAV-1 distribution around the nucleus and at the edge of plasma membrane in control aortic 
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ECs as labelled with yellow arrows (a2). STZ-diabetic ECs showed disrupted CAV-1 
distribution with less fluorescence light emission (b2). Images were combined to merge 
endothelial marker (red), nucleus marker (blue) and CAV-1 fluorescence antibody (green) (a3 
& b3). c) Data is mean +/- SEM (N=4-5) of total CAV-1 expression (% of control) in rat aortic 
endothelial cells. STZ diabetic ECs showed a significant reduction in CAV-1 expression 
compared with control aortic ECs. Significance is represented as * P˂0.05 versus control when 
analysed through two tailed unpaired student t-test. 
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Figure 6. Schematic depiction of Ox-LDL effects and potential mechanisms underlying 
diabetic vascular dysfunction. Panel A depicts cholinergic induced aortic endothelium 
dependent vasodilation. Panel B depicts dysfunctional cholinergic induced aortic endothelial 
dependent vasodilation following STZ. NO: nitric oxide; CAV: caveolin-1; eNOS: 
endothelial nitric oxide synthase; Ox-LDL: oxidised low-density lipoprotein; VD: 
vasodilation; CaM: calmodulin; SMCs; smooth muscle cells. 
 
